PC-ART-009 Reference 3 September 2026 10 min read

What Lipfendra Is

Enlicitide is a macrocyclic peptide, sold under the brand name Lipfendra, and it belongs to a class of drugs that until now had only ever been given by injection. PCSK9 inhibitors block a protein that governs how much low-density lipoprotein cholesterol the liver can clear out of the blood. Blocking it lets the liver pull more LDL out of circulation, and LDL is the cholesterol that builds up in artery walls and raises the risk of heart attack and stroke.

The label covers adults with high cholesterol, and adults with an inherited form of it called heterozygous familial hypercholesterolaemia, who need further LDL reduction alongside diet and exercise. What makes the approval notable is not a new mechanism. It is the same mechanism, in a form somebody can swallow with a glass of water.

How It Works

PCSK9 is a protein that finds LDL receptors on liver cells and marks them for destruction. Fewer receptors means less LDL pulled out of the blood, and more of it left circulating. Enlicitide binds to PCSK9 and blocks it, so those receptors survive, keep working, and go on clearing LDL from the bloodstream.

That is the same target the injectable PCSK9 inhibitors hit. The difference is chemistry rather than biology: a macrocyclic peptide is a ring, and the ring is what lets a peptide survive the gut and reach the bloodstream intact, which is what the injectable versions of this class could not do.

This Is a Peptide, and That Is the Achievement

Enlicitide is not a small molecule. It is a macrocyclic peptide — a chain of amino acids joined head to tail into a ring — and that single fact makes this approval a landmark in chemistry as much as in cardiology.

Peptides are not supposed to be able to do this. Swallow one and the stomach's acid and the gut's proteases treat it as food, because that is exactly what it looks like to them. Whatever survives digestion then has to cross the intestinal wall, and peptides are generally too large and too water-loving to get through. That is why this entire drug class has been injected: not because anyone preferred needles, but because the molecules that block PCSK9 well are the molecules the gut destroys.

Macrocyclisation is what changes the odds. Closing the chain into a ring removes the loose ends proteases grab first, locks the molecule into one shape rather than letting it flop between thousands, and tucks away the polar groups that would otherwise stop it crossing a membrane. The result is a peptide with a small molecule's manners and a biologic's grip on its target.

The manufacturing is the part that rarely reaches a press release and deserves to. Merck's published route reaches the finished molecule in 43 steps, with the longest linear sequence cut to 21, and improves yield by roughly a factor of a thousand over the first-generation synthesis. A drug nobody can make at scale is a paper rather than a medicine, and that thousandfold is the distance between the two.

• A ring, not a chain

  Head-to-tail cyclisation removes the free ends digestive enzymes attack first, which is what lets the molecule reach the bloodstream intact rather than being read as protein and taken apart.

• A biologic's grip, taken orally

  PCSK9 is blocked across a broad protein-to-protein interface, which is why antibodies were reached for first. A macrocycle is large enough to cover that surface and still small enough to be absorbed.

• Made at scale

  43 steps, longest linear sequence 21, yield up roughly a thousandfold on the first-generation route. Scale is what turns a synthesis into a supply.

What the Trials Measured

Two phase 3 trials, run under the CORALreef programme, enrolled 3,207 adults with severe hypercholesterolaemia who were already taking maximally tolerated statin therapy. Both compared enlicitide against placebo on top of that background treatment.

In CORALreef Lipids, which enrolled patients with atherosclerotic cardiovascular disease or at high risk of it, Lipfendra produced a 56% reduction in LDL cholesterol at 24 weeks compared with placebo. In CORALreef HeFH, in patients with the inherited form, the reduction was 59%. Across the programme, the figure quoted is up to 60% LDL lowering on top of high-intensity statins and other background therapies.

That last phrase is the part worth pausing on. These are not reductions against nothing. They are reductions on top of the treatment those patients were already getting, which is the situation the drug is actually prescribed into.

• Powerful LDL reduction

  56% at 24 weeks in CORALreef Lipids, 59% in CORALreef HeFH, both against placebo and both on top of maximally tolerated statin therapy.

• No needles

  The cholesterol-lowering power of the older injectable PCSK9 inhibitors, without the self-injections — which matters for patients uncomfortable with needles and for prescribers who have been slow to reach for the injectable versions.

• Complements statins

  It can be taken alongside a statin, or used as an alternative for someone who cannot tolerate one. In the trials it was always an addition, never a replacement.

How the Label Says to Take It

One 20 mg tablet, once daily, in the morning on an empty stomach. Swallow it whole — do not split, crush or chew it. Take it with water, black coffee or plain tea, and nothing else.

Then wait. The label asks for at least 30 minutes after the tablet before eating, or before drinking anything other than water, black coffee or plain tea. Store the bottle at room temperature, 68°F to 77°F (20°C to 25°C), in the original bottle with the lid tightly closed. There is a moisture absorber in the bottle, and it stays there.

Side Effects on the Label

Most people experience no side effects. In the first trial, the frequency of adverse reactions was similar between the enlicitide group and the placebo group.

In the HeFH trial, two side effects occurred more often with Lipfendra than with placebo: dizziness, in 9% of the Lipfendra group against 4% on placebo, and diarrhoea, in 7% against 2%. In both trials, similar proportions of patients in each group stopped treatment because of side effects.

Seek medical help right away for symptoms of a serious allergic reaction — swelling of the face or throat, trouble breathing, or hives.

Why This Matters

Cardiovascular disease remains the leading cause of death in the United States, and elevated LDL cholesterol is one of its most important modifiable risk factors. High cholesterol usually causes no symptoms at all, so a great many people do not know they have it until a routine blood test says so.

The case for calling this a major moment does not rest on the size of the LDL reduction. Injectable PCSK9 inhibitors have delivered reductions of this order for years, and the class has still not moved population-level outcomes the way its potency suggested it should. The gap between what a drug does in a trial and what it does in a population is almost never pharmacology. It is whether people take it.

That is where a tablet earns its place. A fortnightly injection requires a prescription, a pharmacy that stocks it, a fridge, a technique somebody has to be taught, and a decision to repeat all of it twice a month for the rest of a life. Every one of those is a place to fall out of treatment, and people do — which is part of why prescribers have been slow to reach for the injectables even where they are plainly indicated. A drug somebody will actually take every morning does more work than a better drug somebody stops collecting.

The longevity argument follows from arithmetic rather than from optimism. LDL is not merely a marker of atherosclerosis, it is a cause of it, and risk tracks cumulative lifetime exposure — how much LDL has passed through an artery wall, over how many years. Lowering it earlier and for longer is therefore worth more than lowering it harder and later. A daily oral option is the first version of this class that somebody in their forties with an inherited risk might realistically stay on for decades, and decades is the unit that matters.

What none of that establishes is that anyone lives longer. CORALreef Outcomes is the trial that asks the question directly — major adverse cardiovascular events as the primary endpoint, roughly six years of follow-up, inside a programme enrolling around 17,000 patients — and it has not reported. Until it does, what is on file is a drug that lowers a causal risk factor a great deal, in a form people are more likely to keep taking, and a hypothesis about what that will be worth.

One thing this drug is not, and the confusion is common enough to be worth stating plainly: it is not a blood pressure treatment. PCSK9 has no established relationship with blood pressure, plasma levels of it do not track with blood pressure in people who have hypertension, and neither the label nor the CORALreef results claim an effect on it. Cholesterol and blood pressure are two separate risks that happen to share a specialty and a waiting room. This addresses one of them.

Glossary

The terms this article uses, defined once.

Atherosclerotic cardiovascular disease (ASCVD)

A condition where plaque builds up inside arteries, narrowing them and restricting blood flow, which can lead to heart attack or stroke.

CORALreef trials

The phase 3 clinical trials — CORALreef Lipids and CORALreef HeFH — that evaluated the efficacy and safety of enlicitide.

HeFH (heterozygous familial hypercholesterolaemia)

An inherited condition affecting how the body removes cholesterol from the blood, leading to very high LDL levels from birth.

Hypercholesterolaemia

Too much LDL cholesterol in the blood.

LDL cholesterol

Low-density lipoprotein cholesterol — often called bad cholesterol, because excess amounts build up in artery walls.

Lipid panel

A blood test that measures cholesterol and triglyceride levels.

MACE (major adverse cardiovascular events)

The composite endpoint cardiovascular outcome trials are judged on, typically combining cardiovascular death, heart attack and stroke. It is the endpoint of CORALreef Outcomes, which has not reported.

Macrocyclic peptide

A peptide whose amino acid chain is closed into a ring. The ring removes the loose ends digestive enzymes attack first and holds the molecule in a single shape, which is what allows some macrocycles to be swallowed rather than injected. Enlicitide is one.

Oral bioavailability

The fraction of a swallowed dose that reaches the bloodstream intact. For most peptides it is close to zero, which is the problem macrocyclisation is solving here.

PCSK9

Proprotein convertase subtilisin/kexin type 9 — a protein that regulates LDL cholesterol levels in the blood by marking LDL receptors for destruction.

PCSK9 inhibitor

A class of drugs that block the PCSK9 protein, allowing the liver to remove more LDL cholesterol from the blood.

Placebo

An inactive substance used in clinical trials as a comparison to the active drug.

Statin

A common class of cholesterol-lowering medications that reduce the liver's production of cholesterol.

Sources and evidence